logo

Lenva

Lenvatinib is FDA approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC). It is a multiple receptor tyrosine kinase inhibitor that demonstrates potent antiangiogenic properties.

Features

Product Name Lenva
Generic Name Lenvatinib Mesylate
Therapeutic Class TKI
Formulation Solid
Available Pack Size 2x8's, 2x6's
Available Strength 4 mg, 10 mg
View Prescribing Information Visit Website